Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFS Provident Financial Services Inc

休市中 07-26 16:00:00 EDT

19.01

+0.45

+2.42%

盘后19.01

+0.000.00%

16:10 EDT

最高19.16	最低17.31	成交量108.92万
今开18.14	昨收18.56	日振幅9.99%
总市值24.69亿	流通市值23.95亿	总股本1.30亿
成交额2,054万	换手率0.86%	流通股本1.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident Financial Services Inc","latestPrice":19.01,"timestamp":1722024000000,"preClose":18.56,"halted":0,"volume":1089187,"hourTrading":{"tag":"盘后","latestPrice":19.01,"preClose":19.01,"latestTime":"16:10 EDT","volume":34223,"amount":650579.23,"timestamp":1722024605406},"delay":0,"floatShares":126000000,"shares":129899663,"eps":1.599292,"marketStatus":"休市中","marketStatusCode":7,"change":0.45,"latestTime":"07-26 16:00:00 EDT","open":18.14,"high":19.16,"low":17.305,"amount":20537878.895985,"amplitude":0.099946,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.599292,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1722240000000},"adr":0,"listingDate":1042693200000,"adjPreClose":18.56,"adrRate":0,"dividendRate":0.0505,"preHourTrading":{"tag":"盘前","latestPrice":19.09,"preClose":18.56,"latestTime":"09:19 EDT","volume":1545,"amount":28676.25987,"timestamp":1721999949057},"postHourTrading":{"tag":"盘后","latestPrice":19.01,"preClose":19.01,"latestTime":"16:10 EDT","volume":34223,"amount":650579.23,"timestamp":1722024605406},"volumeRatio":1.1065811273021127,"impliedVol":0.4065,"impliedVolPercentile":0.4524},"requestUrl":"/m/hq/s/PFS/tweets","defaultTab":"tweets","newsList":[{"id":"2454333438","title":"Provident Financial Services Inc 公布截至 6 月的季度业绩 - 盈利摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2454333438","media":"Reuters","labels":["express"],"top":-1,"share":"https://www.laohu8.com/m/news/2454333438?lang=zh_cn&edition=full","pubTime":"2024-07-26 05:57","pubTimestamp":1721944624,"startTime":"0","endTime":"0","summary":"   * Provident Financial Services Inc   报告，在截至6月底的季度里，该公司调整后每股亏损11美分，低于去年同期的每股收益43美分。五位分析师对该季度的平均预期是每股收益 35 美分。华尔街预期为每股收益 15 美分至 43 美分。* Provident Financial Services Inc 公布的本季度每股收益为亏损 11 美分。* Provident Financial Services Inc 本季度股价上涨了 25.4%，今年迄今为止下跌了 0.2%。7月25日 - 预测变化   * 过去三个月，分析师的平均盈利预期下降了约 1.1%。华尔街对 Provident Financial Services Inc 的 12 个月目标价中位数为 18.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2454333435","title":"Provident Financial Services Inc 公布截至 6 月的季度业绩 - 盈利摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2454333435","media":"Reuters","labels":["express"],"top":-1,"share":"https://www.laohu8.com/m/news/2454333435?lang=zh_cn&edition=full","pubTime":"2024-07-26 05:57","pubTimestamp":1721944624,"startTime":"0","endTime":"0","summary":"   * Provident Financial Services Inc   报告，在截至6月底的季度里，该公司调整后每股亏损11美分，低于去年同期的每股收益43美分。五位分析师对该季度的平均预期是每股收益 35 美分。华尔街预期为每股收益 15 美分至 43 美分。* Provident Financial Services Inc 公布的本季度每股收益为亏损 11 美分。* Provident Financial Services Inc 本季度股价上涨了 25.4%，今年迄今为止下跌了 0.2%。7月25日 - 预测变化   * 过去三个月，分析师的平均盈利预期下降了约 1.1%。华尔街对 Provident Financial Services Inc 的 12 个月目标价中位数为 18.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2453096780","title":"Provident Financial Services Inc    预计每股收益 35 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2453096780","media":"Reuters","labels":["preview"],"top":-1,"share":"https://www.laohu8.com/m/news/2453096780?lang=zh_cn&edition=full","pubTime":"2024-07-24 05:59","pubTimestamp":1721771991,"startTime":"0","endTime":"0","summary":"   * Provident Financial Services Inc     将于7月25日公布截至2024年6月30日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，5位分析师的平均预期显示，这家总部位于新泽西州泽西城的公司的营收将从去年同期的9911万美元增长19.6%，达到1.18545亿美元。* LSEG 分析师对 Provident Financial Services Inc 的平均预期为每股收益 35 美分。* 华尔街对 Provident Financial Services Inc 的 12 个月目标价中位数为 18.00 美元，低于其最新收盘价 18.28 美元。7月23日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS"],"gpt_icon":0},{"id":"2453767833","title":"氨基一周｜BD不应该“神秘化”； 第七个被治愈的艾滋病患者出现了","url":"https://stock-news.laohu8.com/highlight/detail?id=2453767833","media":"氨基观察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453767833?lang=zh_cn&edition=full","pubTime":"2024-07-22 11:13","pubTimestamp":1721618012,"startTime":"0","endTime":"0","summary":"\"氨基一周\"致力于提供\"全球最重要的大健康产业新闻分析\"，深入挖掘行业动态，洞察市场趋势。无论您是行业从业者还是对大健康产业感兴趣的读者，\"氨基一周\"都将是您了解行业脉动的得力助手。欢迎关注我们，一起探索大健康产业的无限可能。本周，\"氨基一周\"带来的产业动态分析要点包括：BD不应该越来越“神秘”第七个被治愈的...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240722A037XG00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240722A037XG00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4504","LU1032955483.USD","BK4550","LU0114720955.EUR","LU0889566641.SGD","LU1162221912.USD","LU0795875086.SGD","LU1221951129.SGD","LU1430594728.SGD","LU1732799900.SGD","LU0345770308.USD","LU0466842654.USD","LU1059921491.USD","LU1929549753.HKD","JNJ","BK4195","LU1066053197.SGD","LU2602419157.SGD","LU1935042991.SGD","IE00BSNM7G36.USD","06978","LU1196500208.SGD","LU1066051225.USD","BK4007","LU0640476718.USD","LU0795875169.SGD","LU1244550221.USD","BK4592","IE000M9KFDE8.USD","BK4581","SG9999002224.SGD","LU1506573853.SGD","LU0882574055.USD","LU1032466523.USD","PFS","LU0345770993.USD","BK4585","BK4157","BK1161","BK4559","LU1221951046.USD","BMI","LU2133065610.SGD","BK1574","LU1244550494.USD","BK4588","BK4568","IE00B19Z3581.USD","LU1066051498.USD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2452494118","title":"公积金金融服务盘中异动 急速拉升5.08%报17.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452494118","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452494118?lang=zh_cn&edition=full","pubTime":"2024-07-17 02:33","pubTimestamp":1721154824,"startTime":"0","endTime":"0","summary":"北京时间2024年07月17日02时33分，公积金金融服务股票出现异动，股价急速上涨5.08%。截至发稿，该股报17.57美元/股，成交量42.2773万股，换手率0.32%，振幅4.19%。公积金金融服务股票所在的银行行业中，整体涨幅为1.20%。该公司的业务仅限于金融服务行业，包括向客户提供传统银行和其他金融服务。该公司有一个单一报告部门用于财务报告目的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717023345941f7824&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717023345941f7824&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2451386469","title":"港股异动 | 康方生物(09926)涨超5% 卡度尼利一线治疗晚期宫颈癌III期研究达PFS和OS双主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2451386469","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451386469?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:58","pubTimestamp":1721098724,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物涨超5%，截至发稿，涨5.19%，报40.55港元，成交额1.68亿港元。消息面上，康方生物今日宣布，公司独立自主研发的PD-1/CTLA-4双特异性抗体卡度尼利（开坦尼）联合含铂化疗+/-贝伐珠单抗对比安慰剂联合含铂化疗＋/-贝伐珠单抗用于一线治疗持续、复发或转移性宫颈癌的III期临床研究在期中分析中达到总生存期主要研究终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4211","IE00B5MMRT66.SGD","LU2488822045.USD","LU1794554557.SGD","LU0348784397.USD","BK4134","HSCEI","PFS","07226","LU0348783233.USD","BK1574","BK4195","IE00B543WZ88.USD","YANG","IE00BPRC5H50.USD","III","LU1720050803.USD","LU0417516571.SGD","09926","HSTECH"],"gpt_icon":0},{"id":"2451977622","title":"公积金金融服务盘中异动 大幅上涨5.04%报16.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451977622","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451977622?lang=zh_cn&edition=full","pubTime":"2024-07-15 23:23","pubTimestamp":1721057024,"startTime":"0","endTime":"0","summary":"北京时间2024年07月15日23时23分，公积金金融服务股票出现异动，股价急速拉升5.04%。截至发稿，该股报16.88美元/股，成交量22.8078万股，换手率0.18%，振幅3.24%。公积金金融服务股票所在的银行行业中，整体涨幅为1.13%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240715232344941f7153&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240715232344941f7153&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2450366517","title":"公积金金融服务盘中异动 早盘大幅上涨5.00%报15.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450366517","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450366517?lang=zh_cn&edition=full","pubTime":"2024-07-11 22:14","pubTimestamp":1720707271,"startTime":"0","endTime":"0","summary":"北京时间2024年07月11日22时14分，公积金金融服务股票出现波动，股价急速上涨5.00%。截至发稿，该股报15.85美元/股，成交量11.3128万股，换手率0.09%，振幅2.62%。公积金金融服务股票所在的银行行业中，整体涨幅为0.26%。该公司有一个单一报告部门用于财务报告目的。消息层面，截至22时14分，《加皇资本市场维持Provident Financial Services买入评级，下调目标价至18美元》资讯为影响公积金金融服务的重要信息。根据TipRanks数据显示，该分析师近一年总胜率为53.6%，总平均回报率为13.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711221432aef93ee3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711221432aef93ee3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4211","PFS","BK4195"],"gpt_icon":0},{"id":"2450889070","title":"加拿大皇家银行：维持Provident Finl Servs(PFS.US)评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2450889070","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450889070?lang=zh_cn&edition=full","pubTime":"2024-07-10 09:21","pubTimestamp":1720574479,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Provident Finl Servs(PFS.US)评级，由优于大市调整至优于大市评级,目标价由19.00美元调整至18.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407100937099f29596d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407100937099f29596d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RY","PFS"],"gpt_icon":0},{"id":"2449235312","title":"罗氏重磅双特异性抗体Vabysmo再获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2449235312","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449235312?lang=zh_cn&edition=full","pubTime":"2024-07-06 10:38","pubTimestamp":1720233490,"startTime":"0","endTime":"0","summary":"今日，罗氏宣布，美国FDA批准其双特异性抗体Vabysmo6.0 mg单剂量预填充注射器用于治疗新生血管性或湿性年龄相关性黄斑变性、糖尿病黄斑水肿和视网膜静脉阻塞引起的黄斑水肿。这三种疾病合计影响全球近8000万人。Vabysmo PFS是获FDA批准用于治疗可能导致失明视网膜疾病的首个预填充双特异性抗体注射器。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/06103841412688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2447363126","title":"公积金金融服务盘中异动 下午盘股价大涨5.06%报14.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2447363126","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447363126?lang=zh_cn&edition=full","pubTime":"2024-06-29 02:49","pubTimestamp":1719600554,"startTime":"0","endTime":"0","summary":"北京时间2024年06月29日02时49分，公积金金融服务股票出现异动，股价快速拉升5.06%。截至发稿，该股报14.33美元/股，成交量36.4249万股，换手率0.28%，振幅3.81%。最近的财报数据显示，该股实现营业收入1.85亿美元，净利润32.08百万美元，每股收益0.43美元，毛利数据暂无，市盈率8.94倍。公积金金融服务股票所在的银行行业中，整体涨幅为0.65%。该公司有一个单一报告部门用于财务报告目的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240629024914968180f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240629024914968180f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2440485178","title":"信达生物在2024年美国临床肿瘤学会（ASCO）年会口头报告全球首创抗CLDN18.2/CD3双特异性抗体（IBI389）治疗晚期胰腺癌和胃癌的两项临床研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2440485178","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440485178?lang=zh_cn&edition=full","pubTime":"2024-06-03 09:31","pubTimestamp":1717378260,"startTime":"0","endTime":"0","summary":"临床前结果表明，即使在CLDN18.2低表达的细胞系中，IBI389仍能与肿瘤细胞结合，表现出明显的抗肿瘤效力。而在本次公布的临床数据中，IBI389在包括CLDN18.2中低表达人群在内的晚期胃癌和胰腺癌均展现出有潜力的疗效信号。特别是，作为全球首个公布临床数据的靶向CLDN18.2/CD3双抗，IBI389在胰腺癌中观察到明显获益信号，实现了该创新药物形式在难治癌种领域的突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4428967_ZH28967_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK4211","IE00B19Z4B17.USD","BK1589","IE00B66KJ199.SGD","BK1583","CRS","IE0031619046.USD","PFS","BK4006","BK4213","01801","BK4139","IVBIY","LU1969619763.USD","IE00B7SZL793.SGD","BK4195","LU2328871848.SGD","PR"],"gpt_icon":0},{"id":"2440193448","title":"信达生物宣布他雷替尼（ROS1抑制剂）关键临床II期TRUST-I研究更新数据在美国临床肿瘤学杂志（JCO）发表并于2024年美国临床肿瘤学会（ASCO）年会口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2440193448","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440193448?lang=zh_cn&edition=full","pubTime":"2024-06-02 08:00","pubTimestamp":1717286400,"startTime":"0","endTime":"0","summary":"基于关键临床II期TRUST-I研究的积极结果，他雷替尼两项NDA获中国国家药品监督管理局药品审评中心受理并授予优先审评资格，分别用于局部晚期或转移性ROS1阳性非小细胞肺癌成人患者的一线和二线治疗。TRUST-I研究结果更新进一步证实了他雷替尼的优异疗效和良好安全性，有望为ROS1阳性NSCLC患者带来新的治疗选择。TRUST-II研究结果于《临床肿瘤学杂志》上发表，题为\"Efficacy and Safety of Taletrectinib in Chinese Patients with ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study\"，访问链接：. 在2024年美国临床肿瘤学会（ASCO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4428963_ZH28963_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4007","CDE","BK1583","BK4139","LU2328871848.SGD","BK1161","BK1589","NUVB","LU1969619763.USD","PFS","BK4195","01801","BK4211","IVBIY","BK4017"],"gpt_icon":0},{"id":"2439793409","title":"利好引爆！盘中暴涨超80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439793409","media":"证券时报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439793409?lang=zh_cn&edition=full","pubTime":"2024-05-31 12:52","pubTimestamp":1717131128,"startTime":"0","endTime":"0","summary":"今天上午A股市场继续窄幅震荡，多数板块和个股上行。国防军工、计算机、社会服务等板块涨幅居前。上午A股市场总体表现相对平淡，但有A股公司股票和可转债盘中双双封住涨停。港股市场上午整体表现较好，有港股公司在发布利好公告后，盘中股价一度飙涨超过80%。A股市场整体窄幅震荡今天上午A股市场继续窄幅震荡。行业板块和赛道方面，国防军工、计算机、社会服务等板块涨幅居前。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202405313092293890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4504","NIO.SI","LU0052750758.USD","BK4585","LU0053671581.USD","BK4588","BK4195","BK4161","LU0320764599.SGD","BK4505","NIO","LU0708995583.HKD","BK4099","09866","BK4532","BK4548","EVS.SI","BK4203","BK4574","HR","BK4581","BK4531","ITT","BK4526","BK4534","PFS","BK4211","BK4555","HSTECH","BK4225","BK4509"],"gpt_icon":0},{"id":"2439980349","title":"全球首创！市值400亿港元明星药企重磅发布！股价一度涨超70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439980349","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439980349?lang=zh_cn&edition=full","pubTime":"2024-05-31 09:55","pubTimestamp":1717120504,"startTime":"0","endTime":"0","summary":"全球首创！市值400亿港元明星药企重磅发布！股价一度涨超70%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202405313092168659.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202405313092168659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B5MMRT66.SGD","BK1574","LU1720050803.USD","LU1794554557.SGD","BK4179","LU0348783233.USD","BK4211","BK1161","IE00B543WZ88.USD","LU0348784397.USD","PFS","BK4563","09926","BK4195","LU0417516571.SGD","IO"],"gpt_icon":0},{"id":"2439982192","title":"康方生物涨近40% AK112–303达到PFS优效显著阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2439982192","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439982192?lang=zh_cn&edition=full","pubTime":"2024-05-31 09:42","pubTimestamp":1717119778,"startTime":"0","endTime":"0","summary":"金融界5月31日消息，周五早盘，康方生物(09926.HK)涨39.75%。消息方面，该公司自主研发的全球首创双特异性抗体新药依达方对比帕博利珠单药一线治疗PD-L1表达阳性（PD-L1 TPS≥1%）的局部晚期或转移性非小细胞肺癌（NSCLC）的注册性III期临床试验AK112–303（HARMONi-2），达到无进展生存期(PFS)优效显着阳性结果。\n\n\r\n            责任编辑：栎树","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/31094240843229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1794554557.SGD","PFS","BK4195","IE00B5MMRT66.SGD","LU1720050803.USD","09926","BK1161","LU0348784397.USD","BK4211","LU0417516571.SGD","IE00B543WZ88.USD","BK1574","LU0348783233.USD"],"gpt_icon":0},{"id":"2439981703","title":"港股异动 | 康方生物(09926)高开15% AK112–303达到PFS优效显著阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2439981703","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439981703?lang=zh_cn&edition=full","pubTime":"2024-05-31 09:21","pubTimestamp":1717118497,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物高开15%，截至发稿，涨15%，报36.8港元，成交额1092.96万港元。消息面上，康方生物公布，其自主研发的全球首创双特异性抗体新药依达方对比帕博利珠单药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的注册性III期临床试验AK112–303，由独立数据监察委员会进行的预先设定的期中分析显示达到无进展生存期的主要研究终点。依沃西组总体安全性良好，无新的安全性信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1128806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1794554557.SGD","HSTECH","HSCEI","09926","BK1574","07226","IE00B5MMRT66.SGD","LU0417516571.SGD","LU1720050803.USD","YANG","LU0348784397.USD","LU0348783233.USD","BK4211","IE00B543WZ88.USD","BK1161","PFS","BK4195"],"gpt_icon":0},{"id":"2439739985","title":"康方生物：AK112–303达到PFS优效显著阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2439739985","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439739985?lang=zh_cn&edition=full","pubTime":"2024-05-31 08:28","pubTimestamp":1717115280,"startTime":"0","endTime":"0","summary":"　　康方生物发布公告，该公司自主研发的全球首创双特异性抗体新药依达方对比帕博利珠单药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的注册性III期临床试验AK112–303，由独立数据监察委员会进行的预先设定的期中分析显示达到无进展生存期的主要研究终点。依沃西组的患者，包括PD-L1低表达，PD-L1高表达，以及其他高风险患者，均临床获益显著。股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-31/doc-inaxakrk4126420.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-31/doc-inaxakrk4126420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0348784397.USD","BK1574","BK4195","IE00B5MMRT66.SGD","LU1794554557.SGD","BK1161","LU0417516571.SGD","PFS","09926","LU0348783233.USD","LU1720050803.USD","IE00B543WZ88.USD","BK4211"],"gpt_icon":0},{"id":"2439602814","title":"康方生物(09926)：AK112–303达到PFS优效显著阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2439602814","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439602814?lang=zh_cn&edition=full","pubTime":"2024-05-31 06:40","pubTimestamp":1717108816,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，该公司自主研发的全球首创双特异性抗体新药依达方对比帕博利珠单药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的注册性III期临床试验AK112–303，由独立数据监察委员会进行的预先设定的期中分析显示达到无进展生存期的主要研究终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1128755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","BK1574","LU1794554557.SGD","LU0348783233.USD","BK4211","BK1161","IE00B543WZ88.USD","LU0348784397.USD","PFS","09926","BK4195","LU0417516571.SGD","LU1720050803.USD"],"gpt_icon":0},{"id":"2439586877","title":"健康巡回：试验性疗法可延缓晚期结肠癌的发展，提高生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2439586877","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439586877?lang=zh_cn&edition=full","pubTime":"2024-05-29 02:04","pubTimestamp":1716919480,"startTime":"0","endTime":"0","summary":"今天，我们将在本周末举行的本年度最重要的肿瘤学会议上重点介绍另一项研究，该研究是一种联合疗法，可延缓晚期结肠癌的进展并提高其生存率。Arcus疗法可延缓晚期结直肠癌的发展一项中期试验的数据显示，Arcus生物科学公司  正在开发一种新的治疗方法，其中包括一对实验性免疫疗法药物，它对那些尽管接受了标准治疗但晚期结直肠癌仍继续扩散的患者显示出了良好的效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","BK4139","RCUS","PFS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.provident.bank","stockEarnings":[{"period":"1week","weight":0.0716},{"period":"1month","weight":0.4229},{"period":"3month","weight":0.2598},{"period":"6month","weight":0.0704},{"period":"1year","weight":-0.0052},{"period":"ytd","weight":0.0544}],"compareEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":-0.002},{"period":"3month","weight":0.0712},{"period":"6month","weight":0.117},{"period":"1year","weight":0.2032},{"period":"ytd","weight":0.1454}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Provident Financial Services, Inc.是一家特拉华州公司，于2003年1月15日成为Provident Bank的控股公司。该公司通过其子公司银行开展业务，该银行是一家面向社区和客户的银行，目前在新泽西州北部和中部以及宾夕法尼亚州的雄鹿县、利哈伊县和北安普敦县以及纽约州的拿骚县和皇后区经营全方位服务的分行和贷款生产办事处。该银行还通过其全资子公司Beacon Trust Company提供信托和财富管理服务，并通过其全资子公司Provident Protection Plus, Inc.提供保险服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.028736},{"month":2,"riseRate":0.409091,"avgChangeRate":-0.014442},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.001162},{"month":4,"riseRate":0.5,"avgChangeRate":0.008294},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.013005},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.002657},{"month":7,"riseRate":0.636364,"avgChangeRate":0.041971},{"month":8,"riseRate":0.47619,"avgChangeRate":-0.011999},{"month":9,"riseRate":0.380952,"avgChangeRate":-0.016518},{"month":10,"riseRate":0.666667,"avgChangeRate":0.037244},{"month":11,"riseRate":0.666667,"avgChangeRate":0.02828},{"month":12,"riseRate":0.571429,"avgChangeRate":0.018079}],"exchange":"NYSE","name":"Provident Financial Services Inc","nameEN":"Provident"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Provident Financial Services Inc,PFS,Provident Financial Services Inc股票,Provident Financial Services Inc股票老虎,Provident Financial Services Inc股票老虎国际,Provident Financial Services Inc行情,Provident Financial Services Inc股票行情,Provident Financial Services Inc股价,Provident Financial Services Inc股市,Provident Financial Services Inc股票价格,Provident Financial Services Inc股票交易,Provident Financial Services Inc股票购买,Provident Financial Services Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况